Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP509251.RAp1MGPqx-rXy_dkaczc6QtbdmG0VpqZNJzZBxhziuZn8130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP509251.RAp1MGPqx-rXy_dkaczc6QtbdmG0VpqZNJzZBxhziuZn8130_provenance.
• NP533550.RAvZFGXtRXb_j_R0bZ5OVmZJJ4up_iDBapq26mxMBAwRQ130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP533550.RAvZFGXtRXb_j_R0bZ5OVmZJJ4up_iDBapq26mxMBAwRQ130_provenance.
• NP599726.RApXGn93VM5PM5QsnBaekPWyhWbwGQZC5k6KLKgPwI1WI130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP599726.RApXGn93VM5PM5QsnBaekPWyhWbwGQZC5k6KLKgPwI1WI130_provenance.
• NP826796.RAtI3eSpyT1ioDrDRs4Y0TIvUI4979QLk47eQRd-dSVuM130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP826796.RAtI3eSpyT1ioDrDRs4Y0TIvUI4979QLk47eQRd-dSVuM130_provenance.
• NP764019.RAcGBKEy-4gqcT78uMc4a8DSy071-JNvmt8gniFuDe7fo130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP764019.RAcGBKEy-4gqcT78uMc4a8DSy071-JNvmt8gniFuDe7fo130_provenance.
• NP736735.RAeGIjOx_1ko1nLATFUnndvBYNzWwo81Q8pd8FbLfxU5Q130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP736735.RAeGIjOx_1ko1nLATFUnndvBYNzWwo81Q8pd8FbLfxU5Q130_provenance.
• assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP718328.RAJ-ftSRB2nLwuzV23Xou6wnScjgnQIb0YItfAj4nh9Fg130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718328.RAJ-ftSRB2nLwuzV23Xou6wnScjgnQIb0YItfAj4nh9Fg130_provenance.
• NP790504.RAuK_ElDmQvnALn71kCCS6t6Tzn9R7X1JyVhPiBFLmjIA130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP790504.RAuK_ElDmQvnALn71kCCS6t6Tzn9R7X1JyVhPiBFLmjIA130_provenance.
• NP736602.RAGx6_fSnELu02mlMwzRP4bGlYnP2FfB4m1Vmex67KQvY130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP736602.RAGx6_fSnELu02mlMwzRP4bGlYnP2FfB4m1Vmex67KQvY130_provenance.
• NP790496.RAPQaGcWl5vcnttLEyLQpX-7jm0CbHWGo_3tAddhMP-1o130_assertion description "[To evaluate the frequency of MPL W515L, W515K and S505N mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) and to determine whether MPLW515L leads to impaired Mpl expression, constitutive STAT3 and STAT5 activation and enhanced response to thrombopoietin (TPO).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP790496.RAPQaGcWl5vcnttLEyLQpX-7jm0CbHWGo_3tAddhMP-1o130_provenance.